Addex Therapeutics Ltd. has announced a significant increase in its issued share capital, aimed at creating treasury shares to enhance its financial flexibility. This move is crucial as it allows the company to better position itself for future financing opportunities while keeping its number of outstanding shares unchanged.

The announcement was made on October 29, 2026, and is part of Addex's ongoing strategy to develop its portfolio of novel small molecule allosteric modulators for neurological disorders. The newly issued shares, totaling 93,000,000 at a nominal value of CHF 0.01, have been fully subscribed by Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics. The shares are now listed on the SIX Swiss Exchange.

Background

Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurological disorders. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Addex's shares are traded on the Nasdaq under the ticker symbol ADXN.

Recent filings include several 6-K reports, with the latest being filed on October 29, 2026, and previous filings on October 8 and October 2, 2026. These filings indicate ongoing activities and developments within the company.

What the Filing Says

The filing states, "The transaction has been executed to provide Addex with additional future financing flexibility." This indicates a strategic move to strengthen the company's financial position.

Impact

This increase in issued share capital may affect various stakeholders, including investors and competitors in the pharmaceutical preparations industry. It reflects Addex's proactive approach to securing its financial future and could influence how similar companies approach their own capital structures.

What's Next

The filing does not specify what happens next regarding the use of these newly created treasury shares or any subsequent actions the company may take.